|
|
Satellite Symposia Program
Friday, June 2, 2006
16:30 – 18:00
THEATRE
(ROOM A)
|
Clinical Management of Osteoporosis
Satellite Symposium presented by
ELI LILLY
Chair: D. GOLTZMAN
Quality of Life in Patients with Osteoporosis: Assessment of Pain and Function
J.D. ADACHI
Maximizing Adherence to Osteoporosis Therapies
D.A. HANLEY
Future Directions in Osteoporosis Therapy: Nonvertebral Fracture Outcomes and Long-term Fracture Risk Assessment
P.D. DELMAS
|
Saturday June 3, 2006
07:00 – 08:30
THEATRE
(ROOM A)
|
Improving Osteoporosis Therapy: A Logical Progression
Special Breakfast Symposium presented by
MSD
Chair: D. HOSKING
Opening Remarks
Patients First
A. SEBBA
Vitamin D: Understanding the Importance
B. DAWSON-HUGHES
A Better Approach to Osteoporosis Patient Care
S. EPSTEIN
Panel Discussion/Q&A
|
16:15 – 17:45
CONSTITUTION HALL
(ROOM B)
|
Expanding the Clinical Picture of Osteoporosis
Satellite Symposium presented by
THE ALLIANCE FOR BETTER BONE HEALTH
Chair: P.D. DELMAS
The Undiagnosed and Untreated Patient
P.D. DELMAS
Current Challenges in Male Osteoporosis
S. BOONEN
Beyond the Spine: The Importance of Diagnosing and Treating Nonvertebral Fractures
J. ADACHI
|
16:15 – 17:45
THEATRE
(ROOM A)
|
Effective Management of Postmenopausal Osteoporosis with Less Frequent Dosing
Satellite Symposium presented by
ROCHE/GSK
Chair: J.Y. REGINSTER
Poor Adherence is Widespread in Clinical Practice and Compromises Patient Outcomes
P. HADJI
Patients' Preference for Once-monthly Ibandronate: The Evidence
M.L. BRANDI
Once-monthly Ibandronate: Meeting Patients' Needs with Efficacy, Safety and Tolerability
M. STONE
Once-monthly Ibandronate: Experience from Clinical Practice
P. HADJI
Options When Oral Dosing is Unsuitable: Intravenous Bisphosphonates
R.R. RECKER
Summary – Expanding Bisphosphonate Treatment Options to Meet Both Physician and Patient Needs
J.Y. REGINSTER
Questions and Answers
|
Sunday June 4, 2006
07:00 – 08:30
THEATRE
(ROOM A)
|
A New Pathway to Bone Health: Emerging Therapeutic Options
Special Breakfast Symposium presented by
AMGEN
Chair: P.D. MILLER
Introduction and Opening Remarks
P.D. MILLER
Optimizing Osteoporosis Therapy: Current Options and Future Directions
P.D. MILLER
Clinical Implications of Abnormalities in the RANK/RANKL/OPG Pathway
L.C. HOFBAUER
RANKL Inhibition as an Evolving Therapeutic Option Across the Bone Loss Continuum
M.M. LUCKEY
Q&A/Closing Remarks
P.D. MILLER
|
16:15 – 17:45
THEATRE
(ROOM A)
|
Long-term Management of Osteoporosis: The Quest for Real-world Effectiveness
Satellite Symposium presented by
NOVARTIS
Co-chairs: S. ADAMI and J. BROWN
Introduction and Opening Remarks
S. ADAMI and J. BROWN
New Challenges in Osteoporosis in the 21st Century
E. SIRIS
Mechanisms and Utility of Bisphosphonates in Metabolic Bone Diseases
S. PAPAPOULOS
Efficacy of Long-acting Bisphosphonates in Metabolic Bone Diseases
J. ADACHI
Closing Remarks
S. ADAMI and J. BROWN
|
16:15 – 17:45
CONSTITUTION HALL
(ROOM B)
|
Redressing the Balance in Postmenopausal Osteoporosis
Satellite Symposium presented by
SERVIER
Co-chairs: H. GENANT and R. JOSSE
Introduction
R. JOSSE
Bone Biology and its Modulation
G. RUSSELL
Strontium Ranelate's Dual Action: A Closer Look
P.J. MARIE
A Broad Range of Antifracture Efficacy
E. SEEMAN
Meeting the Needs of Osteoporotic Patients
S. BOONEN
Conclusion
H. GENANT
|
Monday June 5, 2006
07:00 – 08:30
THEATRE
(ROOM A)
|
Beyond Conservative Care: Minimally Invasive Treatment for Vertebral Compression Fractures
Special Breakfast Symposium presented by
KYPHON
Is Conservative Management Conservative? The Impact of Vertebral Body Compression Fractures Treated Non-operatively on Health and Quality of Life
S. BOONEN
Minimally Invasive Surgery for VCFs: Indications, Contraindications and Outcomes
E. TRUMEES
Fracture Reduction Evaluation (FREE) – Update on Multi-center Prospective Randomized Controlled Clinical Trial Comparing Balloon Kyphoplasty to Non-surgical Management
D. WARDLAW
|
16:15 – 17:45
THEATRE
(ROOM A)
|
Clinical Perspectives: Use of Anabolic Therapy in the Management of Osteoporosis
Satellite Symposium presented by
NPS PHARMACEUTICALS
Chair: J.P. BILEZIKIAN
Welcome/Opening Remarks
J.P. BILEZIKIAN
Fracture Risk: Identifying Patients for Therapeutic Intervention
S. SILVERMAN
Parathyroid Hormone and Bone Health
R. HEANEY
Clinical Considerations and Optimization of Anabolic Therapy
J.P. BILEZIKIAN
Panel Discussion/Q&A
|
16:15 – 17:45
CONSTITUTION HALL
(ROOM B)
|
The Development of Tibolone for Prevention and Treatment of Osteoporosis in Postmenopausal Women
Satellite Symposium presented by
ORGANON
Co-chairs: R. LINDSAY and M. MOL
Management of Osteoporosis and Emerging New Treatment Options in Postmenopausal Women
R. LINDSAY
Preclinical Tibolone Research on Bone: Mechanism of Action, Bone Strength and Quality
T. EDERVEEN
The Tissue Selective Clinical Profile of Tibolone: Efficacy and Safety
J.C. GALLAGHER
Design of Tibolone Fracture Trial (LIFT) and Comparative Data versus Raloxifene (STEP)
P.D. DELMAS
|
Page Top
|
|
|
